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An Unusual Recurrence of Miller Fisher Syndrome: Three Times in Eight Years 
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Miller Fisher Syndrome (MFS) is an acute, autoimmune polyneuropathy 
usually associated with a good prognosis which is clinically characterized 
by ataxia, ophtalmoplegia, and areflexia. MFS has a monophasic course, 
double recurrence can be seen in rare cases. But three attacks are very 
rare. In this article, we discussed a rare case of MFS and approach to 
the treatment that recurred 3 times within a period of 8 years. It is 
emphasized that MFS cases may occur a recurring pattern, and plasma 
exchange should be definitely tried as a therapeutic approach when 
clinical deterioration occurs under intravenous immunoglobulin (IVIg) 
therapy.
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ABSTRACT
Miller Fisher Sendromu (MFS) akut, genellikle iyi prognoz ile ilişkili 
otoimmün bir polinöropati olup, klinik olarak ataksi, oftalmopleji 
ve arefleksi ile karakterizedir. MFS monofazik seyirlidir, ikinci tekrar 
nadir vakalarda görülmektedir. Ancak, üç atak oldukça nadirdir. Bu 
yazıda, sekiz yıllık periotta üç kez tekrarlayan nadir bir MFS olgusu ve 
tedaviye yaklaşım tartışılmıştır. MFS’lu olguların tekrarlayıcı bir patern 
gösterebileceği ve plazma değişiminin intravenöz immünglobulin 
(IVIg) tedavisi altında klinik kötüleşmesi olan hastalarda tedavi edici bir 
yaklaşım olarak denenebileceği vurgulanmıştır.
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Miller Fisher Syndrome (MFS) is a subgroup of Guillain-Barré syndrome 
(GBS) and clinically characterized by ataxia, ophtalmoplegia, and areflexia. 
MFS is an acute, autoimmune polyneuropathy usually associated with a 
good prognosis. Despite having a monophasic course, it rarely tends to 
recur. In this article, we discussed a rare case of MFS that recurred 3 times 
within a period of 8 years.
CASE REPORT
A 71-year-old man was admitted to hospital with gait disorder and 
drooping eyelids after an upper respiratory tract infection in 2009. He 
had bilateral ptosis, dysphonic speech, minor paresia, and loss of deep 
tendon reflexes (DTR) in upper and lower extremities. At that time a 
cerebrospinal fluid (CSF) examination had revealed albuminocytological 
dissociation; and an electrophysiological examination had indicated 
sensorimotor polyneuropathy affecting motor and sensory nerves, 
with preserved sural nerve response but lost F responses. He had been 
administered intravenous immunoglobulin (IVIG) for 5 days with MFS 
diagnosis and slight improvement in tetraparesis. Three days after the 
cessation of treatment, however, his neurological examination had 
deteriorated, and he was treated with plasma exchange (PE) theraphy 
for 5 days with partial benefit. Thereafter, he had participated in a 
physiotherapy program, and had completely improved 3 months after. In 
2013 he presented to our hospital after a second attack characterized by 
drooping eyelids, numbness and weakness of extremities. Three months 
prior to that presentation he had begun suffering severe intermittent 
diarrheal attacks. He had bilateral ptosis, limited lateral gaze in both eyes, 
disarthric speech, tetraparesia (bilateral biceps 5-/5, right triceps 4/5, left 
triceps 3+/5, bilateral ankle flexors 5-/5, lower extremity muscle strengths 
4/5), hyporeflexia in upper extremities, and areflexia in lower extremities 
(Figure 1). CSF analysis revealed a glucose level of 92 mg/dl (40–70 mg/
dL) and a protein level of 436 mg/dL (150–450 mg/dL) and antiGQ1b 
was found negative. Autoimmune paraneoplastic antibody testing 
detected serum anti-Yo antibody positivity. A malignancy screening 
consisting of serum tumor marker measurement, abdominal US, and 
thoracic CT examination did not yield a specific diagnosis. A provisional 
diagnosis of MFS was made, for which the patient was treated with IVIg 
at a dose of 0.4 gr/kg. As he developed dysphagia on the 3th and on 
the 4th day of treatment he sustained cardiac and respiratory arrest, and 
was successfully resuscitated, stabilized, and connected to mechanical 
ventilation. He was monitored under mechanical ventilation for 14 days, 
and additionally, underwent PE for 5 days. After he was stabilized, and 
observed for an additional 10 days, after which he was discharged with 
partial improvement of ptosis and minor tetraparesia (4+/5, 5-/5). Having 
attended a physiotherapy program, the patient had his muscle strengths 
almost returned to normal. He was admitted to our hospital with gait 
disorder and drooping eyelids in 2016, for the third time. He had bilateral 
semiptosis with both eyelids being at the level of pupilla, bilaterally limited 
lateral gaze in conjugated eye movements, trunk ataxia, full extremity 
muscle strengths, and abolic DTR. Hemogram, biochemistry tests, and 
intracranial images were normal. As he refused lumbar puncture (LP), CSF 
examination was not possible. An electrophysiological study revealed a 
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sensorineural type polyneuropathy which was characterized by lost 
sensory and F responses but preserved sural nerve response. IVIg was 
begun for 5 days. He was discharged with near-complete correction of 
ptosis and ataxia on the 12th day.
DISCUSSION
MFS cases were published in 1956 by the physician who named the 
syndrome (1). New criteria have been studied for defining subtypes. 
A recent study indicated that electrophysiological studies are more 
important in phenotypic description for defining subtype and 
determining prognosis according to a new GBS clinical classification (2).
Ataxia, ophtalmoplegia, and areflexia are the classical signs of the 
syndrome. Its etiopathogenesis include demyelination and axonal injury 
in peripheral nerves, spinal roots, and cranial nerves due to autoimmunity 
after an infection.
Studies about the signs of MFS have provided evidence of an injury to 
Group Ia neurons in the dorsal root ganglia by circulating antibodies 
as the cause of ataxia (3). Ophtalmoplegia in MFS is rather bilateral 
and symmetrical in character. A case with unilateral onset but bilateral 
progression was also reported, too (4). Our patient had ophtalmoplegia in 
his second and third attacks. Areflexia may not exist in all cases. Normal or 
increased reflex responses can be seen. Bilateral ptosis is a rare sign. Our 
patient had bilateral ptosis in all attacks. A study demonstrated that signs 
and symptoms in subsequent attacks were milder than those in the first 
attack (5). Our patient’s first attack was characterized by ptosis, dysphonic 
speech, minor paresthesia and loss of DTR in extremities; the second attack 
by ptosis, limited lateral gaze, dysarthric speech, tetraparesia, and areflexia; 
and the third attack by semiptosis, ataxia, and ophtalmoplegia. It was noted 
that the third attack had a milder course than the second one.
MFS typically has a monophasic course. However, it rarely tends to 
recur (6). The number of recurrences is usually limited to two. The study 
detected recurrences in 4 of 34 patients, and the first attacks of the 
patients with recurrent MFS tended to occur at a younger age (5). Our 
patient had his first attack at the age of 63 years.
Riche et al. reported an antiGQ1b positive case with 3 attacks within 16 
years (7). Our patient suffered 3 attacks in a period of 8 years. AntiGQ1b 
was only found negative in the second attack. One study reported an inter-
attack period of 2.5–12.5 years (8). Our patient’s first and second attacks 
were spaced by 4 years and the second and third attacks by 3 years.
GBS and its forms may rarely be paraneoplastic in nature. According to 
the criteria for paraneoplastic neurological syndromes (PNS) published 
by Graus et al., the presence of a non-classical neurological syndrome 
and a well-defined onconeural antibody in the absence of cancer is 
definitely defined as a PNS (9). Our patient had recurrent MFS, a non-
classical neurological syndrome, and anti-Yo positivity, a well-defined 
onconeural antibody. Therefore, our patient has been regularly screened 
for malignancy for the possibility of a PNS.
MFS usually portends a favorable prognosis. However, our patient 
had frequent recurrences and a poor clinical course, and he required 
mechanical ventilatory support at intensive care unit. The available 
treatment options include IVIg and PE. However, some contrasting views 
exist in the literature with regard to the treatment. Mori et al. examined 
92 patients with MFS and treatment (28 IVIg, 23 PE, 41 none). They found 
that IVIg therapy slightly hastened the improvement of ophtalmoplegia 
and ataxia, but the times to disappearance of the symptoms were 
comparable in all groups (10). They were of the opinion that IVIg and PE 
did not alter patient outcomes due to the inherent favorable prognosis 
of the disorder (10). Our patient had not sufficiently benefited from IVIg 
therapy and he had even progressed in the first two attacks, but showed 
dramatic improvement with subsequent PE treatment. Our patient had 
response to the standard dose IVIg at last attack.
His all attacks were characterized by a severe clinical course and an 
antecedent infection. He showed a poor response to IVIg but a dramatic 
response to PE at the first two attacks. In clinical practice, physicians 
should remember that, albeit rare, MFS cases may demonstrate a 
recurring pattern, and PE should be definitely tried as a therapeutic 
approach when clinical deterioration occurs under IVIg.
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Figure 1. The patient had bilateral ptosis.
